A coxsackievirus B4 strain and application thereof are disclosed. The strain is named KM140-G01 and is preserved in China Center for Type Culture Collection (CCTCC) on Jun. 18, 2023, and the preservation number is CCTCC NO: V202356, the preservation address is Wuhan University, China. The strain is a humanized coxsackievirus B4 wild type single purified strain, and has strong virus replication capacity, good genetic stability and immunogenicity; the strain can be applied to the development of human coxsackievirus B4 vaccine production strains, and is suitable for the development of attenuated coxsackievirus B4 vaccine and inactivated coxsackievirus B4 vaccine; the method can also be used for establishing an infection model on Vero cells and suckling mice, and is used for CVB4 infection and pathogenic mechanism research, CVB4 vaccine evaluation and antiviral drug screening.

The compositions and methods provided herein include a ribonucleic acid (RNA) encoding a nuclear cytoplasmic transport (NCT) inhibitor protein to improve target protein expression, e.g., a target protein encoded by a DNA vector, a messenger RNA, a self-amplifying RNA, or an RNA comprising an unmodified uridine nucleotide. The compositions and methods provided herein may be used to improve the expression of any target protein, for example a viral protein antigen for use in a vaccine.

Provided herein are engineered cell lines. In some embodiments, cells of an engineered cell line have altered expression of a gene and/or altered expression of an miRNA, wherein the altered expression results in increased or decreased production of a virus. The virus is a picomavirus, such as a poliovirus or Enterovirus 71. Also provided herein are methods for using the engineered cells to produce virus, and methods for treating a subject having or at risk of having a viral infection.

A trivalent transgene that encodes a viral surface glycoprotein component, a viral nucleoprotein component and a viral RNA polymerase component is provided. Vaccines incorporating the trivalent transgene are also provided, along with methods of vaccinating mammals to protect against viral infection.

A T-cell epitope polypeptide of Senecavirus A (SVA) having an amino acid sequence represented by one of SEQ ID NOs: 1-7: SEQ ID NO: 1:

TABLE-US-00001 DEALGRVLTPAAVDEALVDL; SEQIDNO:2: AILAKLGLALAAVTPGLIIL; SEQIDNO:3: KASPVLQYQL; SEQIDNO:4: EMKKLGPVAL; SEQIDNO:5: AHDAFMAGSG; SEQIDNO:6: PPLGDDQIEYLQVLKSLALT; and SEQIDNO:7: LASTLIAQAVSKRLYGSQSV.

Compositions for prevention of Foot and Mouth Disease (FMD) are provided, comprising an antigen component in the amount equivalent to 0.5-20 g FMD virus and an adjuvant component comprising oil, an immunostimulatory oligonucleotide, and a polycationic carrier. Methods of using the composition, as well as the methods of reducing FMD persistence are also provided.

A method of treating cancer in a subject in need thereof includes administering in situ to the cancer a therapeutically effective amount of a virus or virus-like particle.

The present disclosure relates to a pharmaceutical composition comprising a nucleic acid molecule of an adjuvant, a metal complex stabilizing the nucleic acid molecule, and optionally an immunogen that may be a peptide or a protein, or a composition of stabilizing the nucleic acid molecule of the adjuvant comprising the metal complex. The metal complex interacts with the nucleic acid molecule of the adjuvant and/or the immunogen so as to stabilize such pharmaceutically active ingredients, and induces continuous effectiveness of the active ingredients without degradation.

The present invention is directed to novel nucleotide sequences of Senecavirus A (SVA), including novel genotypes thereof, which are useful as live attenuated and other vaccine compositions for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine SVA genotypes and isolates. Diagnostic and therapeutic sequences are also a feature of the present invention, as are infectious clones useful in the propagation of the virus and in the preparation of vaccines. Particularly important aspects of the invention include polynucleotide constructs that replicate in tissue culture and in host swine. The invention also provides for novel full length SVA genomes that can replicate efficiently in host animals and tissue culture.